---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-23-000002"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2023-01-03T23:59:59+00:00"
generated_at: "2026-06-20T20:56:08.976655+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Moderna details 2023 strategic priorities; RSV trial nearly enrolled, flu vaccine accelerated pathway

## Summary
- RSV vaccine Phase 3 enrolled >36,000 of 37,000 target; flu vaccine efficacy trial initiated in Northern Hemisphere.
- Personalized cancer vaccine (mRNA-4157/V940) + KEYTRUDA cut recurrence or death risk by 44% in Phase 2 melanoma study.
- First inhaled mRNA candidate (Vxc-522 for cystic fibrosis) cleared by FDA; relaxin Phase 1B dosed for heart failure.
- Rare disease programs show promise: propionic acidemia MDE reductions; sixth candidate (OTC deficiency) added.
- 2023 priorities include building respiratory franchise, aggressive cancer vaccine program, and potential flu vaccine approval.

## SEC filing metadata
- accession: 0001682852-23-000002
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2023-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000002/0001682852-23-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000002/mrna-20230103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-23-000002
- JSON: https://secwatch.observer/filing/0001682852-23-000002.json
- Plain text: https://secwatch.observer/filing/0001682852-23-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.